Objectives: The focus of the present research is to develop printlet formulations of pyrimethamine (PMT).
Methods: Printlets formulation of PMT were developed by screening design by varying laser scanning speed, Kollidon® VA 64, polyvinylpyrrolidone, and disintegrant.
Results: Laser scanning speed, Kollidon® VA, and disintegrant had statistically significant effect on hardness, disintegration time, and/or dissolution (p < 0.05). Dissolution was almost 100% in 30 min. X-ray powder diffraction indicated partial amorphous transformation of the crystalline drug. Pharmacokinetic and anti-toxoplasma activity profiles of the printlets and compressed tablets were superimposable with no statistical difference (p > 0.05).
Conclusion: Clinical performance of the printlets would be similar to the compressed tablets.
Keywords: Pyrimethamine; anti-toxoplasma activity; dissolution; pharmacokinetic; phase transformation; printlets.